These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 33490224)

  • 1. Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets-a narrative review.
    Samartzis EP; Labidi-Galy SI; Moschetta M; Uccello M; Kalaitzopoulos DR; Perez-Fidalgo JA; Boussios S
    Ann Transl Med; 2020 Dec; 8(24):1712. PubMed ID: 33490224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
    Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
    Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Links between Endometriosis and Endometriosis-Associated Ovarian Cancer-A Narrative Review (Endometriosis-Associated Cancer).
    Pejovic T; Cathcart AM; Alwaqfi R; Brooks MN; Kelsall R; Nezhat FR
    Life (Basel); 2024 May; 14(6):. PubMed ID: 38929687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis.
    Driva TS; Schatz C; Haybaeck J
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes.
    Ma Y; Field NR; Xie T; Briscas S; Kokinogoulis EG; Skipper TS; Alghalayini A; Sarker FA; Tran N; Bowden NA; Dickson KA; Marsh DJ
    Cancers (Basel); 2024 Sep; 16(17):. PubMed ID: 39272926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
    Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
    Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
    J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometriosis-Related Ovarian Cancer: Where Are We Now? A Narrative Review towards a Pragmatic Approach.
    Centini G; Schettini G; Pieri E; Giorgi M; Lazzeri L; Martire FG; Mancini V; Raimondo D; Seracchioli R; Habib N; Fedele F; Zupi E
    J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SMARCA4 loss irrelevant for
    Wagner SK; Moon AS; Howitt BE; Renz M
    Gynecol Oncol Rep; 2023 Dec; 50():101305. PubMed ID: 38033359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of ARID1A in gynecologic cancer.
    Mao TL; Shih IeM
    J Gynecol Oncol; 2013 Oct; 24(4):376-81. PubMed ID: 24167674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.
    Takahashi K; Takenaka M; Okamoto A; Bowtell DDL; Kohno T
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33917230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations.
    Bitler BG; Aird KM; Zhang R
    Mol Cell Oncol; 2016 Jan; 3(1):e1032476. PubMed ID: 27308548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is endometriosis a precancerous lesion? Perspectives and clinical implications].
    Chene G; Caloone J; Moret S; Le Bail-Carval K; Chabert P; Beaufils E; Mellier G; Lamblin G
    Gynecol Obstet Fertil; 2016 Feb; 44(2):106-12. PubMed ID: 26850282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications.
    Fukumoto T; Magno E; Zhang R
    Mol Cancer Res; 2018 Dec; 16(12):1819-1825. PubMed ID: 30037854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
    Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
    J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis.
    Chene G; Ouellet V; Rahimi K; Barres V; Provencher D; Mes-Masson AM
    Int J Gynaecol Obstet; 2015 Jul; 130(1):27-30. PubMed ID: 25912412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
    Wang Q; Wang L; L Y; Ding X; Liu A
    J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel insights on the malignant transformation of endometriosis into ovarian carcinoma.
    Gadducci A; Lanfredini N; Tana R
    Gynecol Endocrinol; 2014 Sep; 30(9):612-7. PubMed ID: 24905724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers.
    Falcone R; Filetti M; Lombardi P; Altamura V; Paroni Sterbini F; Scambia G; Daniele G
    Explor Target Antitumor Ther; 2023; 4(4):716-726. PubMed ID: 37711591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.